LHRH Agonists: Contemporary Issues

[摘要] With the exception of skin cancer, prostate cancer is the most common malignancy among men in the United States. It remains the second leading cause of cancer deaths, accounting for approximately 10% of all cancer-related mortality in US men.1 Since the early 1990s, the epidemiology and management of prostate cancer has profoundly changed, both in the United States and in other developed countries, due in part to the development and widespread use of the prostate-specific antigen (PSA) screening test.1,2 Each year increasing numbers of men are diagnosed with prostate cancer in general, and early-stage disease in particular, and the age at diagnosis continues to decrease.1–4 Currently, more than two-thirds of men are diagnosed with clinically localized disease, and the rate of men presenting with advanced disease continues to decrease.5–8 Between 1992 and 2001 the incidence rate of prostate cancer increased 3.2% (P < .05) among men under age 65 and decreased 4.4% (P < .05) among those over age 65.9,10 Thus the pool of younger men who have been treated for localized prostate cancer and who may develop disease recurrence is increasing.10

[学科分类] 基础医学